The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma

Mantle cell lymphoma (MCL) is a rare, aggressive and incurable subtype of non-Hodgkin’s B-cell lymphoma. The principal barrier is frequent clinical relapse to multiple lines of therapies, including new FDA-approved biologics and cell therapy. Brexucabtagene autoleucel, the first and only FDA approve...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Vivian Changying, Liu, Yang, Jordan, Alexa, McIntosh, Joseph, Li, Yijing, Che, Yuxuan, Jessen, Katti A., Lannutti, Brian J., Wang, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400406/
https://www.ncbi.nlm.nih.gov/pubmed/34454548
http://dx.doi.org/10.1186/s13045-021-01143-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8400406/
https://www.ncbi.nlm.nih.gov/pubmed/34454548
http://dx.doi.org/10.1186/s13045-021-01143-w

Ejemplares similares